Several other brokerages have also issued reports on DBVT. Zacks Investment Research lowered DBV Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, December 28th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of DBV Technologies in a report on Friday, March 4th. Finally, Societe Generale downgraded DBV Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, January 19th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $6.08.
DBV Technologies stock opened at $1.36 on Wednesday. The business’s 50-day simple moving average is $1.46 and its 200-day simple moving average is $2.22. The firm has a market capitalization of $149.86 million, a PE ratio of -1.51 and a beta of 2.20. DBV Technologies has a 52 week low of $1.20 and a 52 week high of $6.88.
Several institutional investors and hedge funds have recently made changes to their positions in DBVT. OLD Mission Capital LLC increased its stake in DBV Technologies by 647.4% in the third quarter. OLD Mission Capital LLC now owns 137,880 shares of the company’s stock valued at $239,000 after acquiring an additional 119,432 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of DBV Technologies during the third quarter worth $36,000. BlackRock Inc. lifted its holdings in shares of DBV Technologies by 60.5% during the third quarter. BlackRock Inc. now owns 22,350 shares of the company’s stock worth $110,000 after purchasing an additional 8,422 shares during the period. Jane Street Group LLC acquired a new position in DBV Technologies in the third quarter valued at $547,000. Finally, ArrowMark Colorado Holdings LLC lifted its holdings in DBV Technologies by 0.6% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,435,366 shares of the company’s stock valued at $7,033,000 after buying an additional 9,145 shares during the period. 32.81% of the stock is currently owned by institutional investors.
DBV Technologies Company Profile (Get Rating)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- The Sherwin-Williams Company Bottoms Above Institutional Support
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
- Whirlpool Is A Steal At These Prices
- Kimberly-Clark Pops On Successful Price Pass-Through
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.